• X
  • LinkedIn

Austin Top 50

  • Animals
  • Auto
  • Beauty & Style
  • Business News
  • Entertainment
  • Food
  • Health
  • Home & Family
  • Podcasts
  • Tech
  • Travel

Latest Business News

  • Purpose Investments Inc. Confirms 2025 Final Capital Gains Distributions for Purpose Tactical Asset Allocation Fund, Purpose Core Equity Income Fund, and Purpose Tactical Thematic Fund

    Purpose Investments Inc. Confirms 2025 Final Capital Gains Distributions for Purpose Tactical Asset Allocation Fund, Purpose Core Equity Income Fund, and Purpose Tactical Thematic Fund

    Purpose Investments Inc.
    February 18, 2026
  • Creative Realities Announces Repurchase of Slipstream Warrants

    Creative Realities Announces Repurchase of Slipstream Warrants

    Creative Realities
    February 18, 2026
  • ModelOp Appoints Dave Trier to CEO As It Enters Next Phase of Growth

    ModelOp Appoints Dave Trier to CEO As It Enters Next Phase of Growth

    ModelOp, Inc.
    February 18, 2026
  • Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

    Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

    Knight Therapeutics
    February 18, 2026
  • Exco Technologies Limited Announces Normal Course Issuer Bid

    Exco Technologies Limited Announces Normal Course Issuer Bid

    Exco Technologies Ltd.
    February 18, 2026
  • Medline announces participation in the Barclays 28th Annual Global Healthcare Conference

    Medline announces participation in the Barclays 28th Annual Global Healthcare Conference

    Medline Inc.
    February 18, 2026
  • Nexxen to Announce Fourth Quarter 2025 Financial Results on March 4, 2026

    Nexxen to Announce Fourth Quarter 2025 Financial Results on March 4, 2026

    Nexxen International Ltd.
    February 18, 2026
  • LAZARD EXPANDS ITS HEALTHCARE SERVICES TEAM WITH ADDITION OF JOHN KOSKI AND ROBERT LOWE

    LAZARD EXPANDS ITS HEALTHCARE SERVICES TEAM WITH ADDITION OF JOHN KOSKI AND ROBERT LOWE

    Lazard Frères & Co. LLC
    February 18, 2026
  • RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

    Daniel J. Edelman Inc. dba Edelman on behalf of itself and its Affiliates
    February 18, 2026
  • HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger

    HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger

    Global Think Group
    February 18, 2026
1 2 3 … 23,187
Next

Channels

Follow Us

  • X
  • LinkedIn

Copyright @ 2025 Tork Media, All Rights Reserved